Inflammatory Bowel Diseases
Conditions
Keywords
IBD, EBI2, G protein coupled receptor, FACS, UBAC2, lymphocyte migration, single nucleotide polymorphism
Brief summary
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will test the influence of rs9557195 genoty (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes, mRNA expression of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migraton assay.
Detailed description
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). EBI2 is a G protein coupled receptors expressed on the immune cells. EBI2 directs migration and activity of immune cells. Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will recruit patients with Crohn's disease and ulcerative colitis, assess epidemiological and clinical parameters (including clinical activity of IBD) draw blood, isolate lymphocytes, DNA and RNA. The investigators will test the influence of rs9557195 genotype (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes (by FACS using an EBI2-antibody), mRNA expression (by qPCR) of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migration assay.
Interventions
None listed
Sponsors
University of Zurich
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Patient with IBD OR healthy volunteer * No major uncontrolled medical/ surgical/ psychiatric condition requiring ongoing management besides IBD in the respective study groups. Well controlled conditions (i.e. medically controlled arterial hypertension, occupational asthma) may be present
Exclusion criteria
none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| EBI2 expression - dependent on rs9557195 allele status (FACS) | at time of inclusion into the study | EBI2 levels in PBMCs will be determined by FACS, and compared according to allele status of rs9557195 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| EBI2 expression - dependent on rs9557195 allele status (RT-PCR) | at time of inclusion into the study | EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195 |
| UBAC2 expression - dependent on rs9557195 allele status (RT-PCR) | at time of inclusion into the study | UBAC2 levels in PBMCs will be determined by RT-PCR, and compared according to 2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195 |
| Motility of PBMCs dependent on rs9557195 allele status (Boyden chamber) | at time of inclusion into the study | motility of PBMCs will be assessed using the Boyden chamber and compared according to allele status of rs9557195 |
| EBI2-expression (FACS) in individuals treated with infliximab vs. vedolizumab | at time of inclusion into the study | We will compare EBI2 expression as determined by FACS in individuals with infliximab and vedolizumab treatment |
| EBI2-expression (FACS) according to gut inflammation | at time of inclusion into the study | We will compare EBI2 expression (determined by FACS) in IBD patients with severe disease, in remission and in healthy volunteers |
Countries
Switzerland
Contacts
Primary ContactBenjamin Misselwitz, MD
Backup ContactRene Roth, MD
Outcome results
None listed